Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital

Annals of Internal Medicine

Volumn 127, Issue 4, 1997, Pages 281-284

  Maisel, William H ^a   Kuntz, Karen M ^a   Reimold, Sharon C ^a   Lee, Thomas H ^a   Antman, Elliott M ^a   Friedman, Peter L ^a   Stevenson, William G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DISOPYRAMIDE; FLECAINIDE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL;

ADULT; ARTICLE; BRADYCARDIA; DRUG INDUCED DISEASE; FEMALE; HEART ATRIUM FIBRILLATION; HEART VENTRICLE ARRHYTHMIA; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; UNIVERSITY HOSPITAL;

EID: 0030854068     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-4-199708150-00004     Document Type: Article

References (16)

1. Ostrander LD Jr, Brandt RL, Kjelsberg MO, Epstein FH. Electrocardiographic findings among the adult population of a total natural community, Tecumseh, Michigan. Circulation. 1965;31:888-98.
2. Hill JD, Mottram EM, Killeen PD. Study of the prevalence of atrial fibrillation in general practice patients over 65 years of age. J R Coll Gen Pract. 1987;37:172-3.
3. Mancini GB, Goldberger AL. Cardioversion of atrial fibrillation: consideration of embolization, anticoagulation, prophylactic pacemaker, and long-term success. Am Heart J. 1982;104:617-21.
4. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. 1990;82:1106-16.
5. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991; 324:781-8.
6. Ruskin JN. The Cardiac Arrhythmia Suppression Trial (CAST) [Editorial]. N Engl J Med. 1989;321:386-8.
7. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 1992; 20:527-32.
8. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with Oral d-Sotalol. Lancet. 1996;348:7-12.
9. Hohnloser SH, van de Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol. 1995;26:852-8.
10. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J. 1986;111:1088-93.
11. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-30.
12. Collett D. Modelling Survival Data in Medical Research. New York: Chapman & Hall; 1994:27-8.
13. Stratmann HG, Kennedy HL. Torsades de pointes associated with drugs and toxins: recognition and management. Am Heart J. 1987;113:1470-82.
14. Akiyama T, Pawitan Y, Campbell WB, Papa L, Barker AH, Rubbert P, et al. Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators. J Am Geriatr Soc. 1992;40:666-72.
15. Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med. 1994;331:785-91.
16. Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med. 1992;117:141-50.